Bohlok Ali, Inchiostro Lisa, Lucidi Valerio, Vankerckhove Sophie, Hendlisz Alain, Van Laethem Jean Luc, Craciun Ligia, Demetter Pieter, Larsimont Denis, Dirix Luc, Vermeulen Peter, Donckier Vincent
Surgical Oncology, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Abdominal Surgery, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Eur J Surg Oncol. 2023 Jan;49(1):217-224. doi: 10.1016/j.ejso.2022.08.006. Epub 2022 Aug 20.
The histological growth pattern (HGP) of colorectal liver metastases (CRLMs) reflects tumor biology and local infiltrating behavior. In patients undergoing surgery for CRLMs, we investigated whether HGP and surgical margin status interact when influencing prognosis.
Clinicopathological data, margin status, and HGP were reviewed in patients who underwent resection of CRLMs. R1 margin was defined when cancer cells were present at any point along the margin. HGPs were scored according to international guidelines, identifying patients with desmoplastic (DHGP) or non-desmoplastic (non-DHGP) CRLMs.
Among 299 patients, 16% had R1 resection and 81% had non-DHGP CRLMs. Non-DHGP was the only predictive factor for R1 resection (18.7% versus 7.4% in DHGP, p = 0.04). Poorer 5-year overall survival was observed in both R1 and non-DHGP groups in univariate analysis (27.6% in R1 versus 45.6% in R0, p = 0.026, and 37.2% in non-DHGP versus 59.2% in DHGP, p = 0.013), whereas non-DHGP but not R1 remained associated with worse prognosis in multivariate analysis. In patients with non-DHGP, R1 margin has no prognostic impact.
In patients undergoing resection of CRLMs, the prognostic value of poor tumor biology, such as in patients with non-DHGP, exceeds that of surgical radicality.
结直肠癌肝转移(CRLMs)的组织学生长模式(HGP)反映了肿瘤生物学特性和局部浸润行为。在接受CRLMs手术的患者中,我们研究了HGP和手术切缘状态在影响预后时是否相互作用。
回顾了接受CRLMs切除术患者的临床病理数据、切缘状态和HGP。当切缘任何部位存在癌细胞时定义为R1切缘。根据国际指南对HGP进行评分,确定促结缔组织增生性(DHGP)或非促结缔组织增生性(非DHGP)CRLMs患者。
在299例患者中,16%为R1切除,81%为非DHGP CRLMs。非DHGP是R1切除的唯一预测因素(DHGP组为7.4%,非DHGP组为18.7%,p = 0.04)。单因素分析显示,R1组和非DHGP组的5年总生存率均较差(R1组为27.6%,R0组为45.6%,p = 0.026;非DHGP组为37.2%,DHGP组为59.2%,p = 0.013),而多因素分析显示,与预后较差相关的是非DHGP而非R1。在非DHGP患者中,R1切缘对预后无影响。
在接受CRLMs切除术的患者中,肿瘤生物学特性差(如非DHGP患者)的预后价值超过手术根治性。